Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
Boulevard Bio, a new biotech startup, has launched with a $65 million seed round to develop targeted autoimmune drugs.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 4.
Source diversity sample: MedCity News · BioPharma Dive · Dealroom · Endpoints News · STAT · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Boulevard Bio has launched with a $65 million seed round to develop targeted autoimmune drugs. The company is backed by Deerfield Management and co-founded by a top autoimmune researcher. Boulevard Bio aims to develop a trio of immunology drugs, with one of its initial targets being an IgAN drug previously developed by Vera Therapeutics.
The company's launch has been reported by several industry outlets, including BioPharma Dive, Dealroom, Endpoints News, STAT, and Fierce Biotech. The reporting emphasizes Boulevard Bio's ambitious goals in the immunology space and its significant initial funding. Endpoints News and Fierce Biotech both mention the company's specific focus on a 'beautiful path to a cure' for autoimmune diseases.
The reporting does not yet specify the exact timeline for Boulevard Bio's drug development or the specific autoimmune conditions it will target. The company's plans for clinical trials and regulatory approvals have not been detailed. The role of the top autoimmune researcher co-founder in the company's strategy is also not fully clear.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Sources (6)
- Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder MedCity News · 11h ago
- Boulevard starts up with $65M to pursue targeted autoimmune drugs BioPharma Dive · 11h ago
- Boulevard Bio launches with $65M seed to chase autoimmune cures Dealroom · 11h ago
- Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drug Endpoints News · 11h ago
- Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies STAT · 11h ago
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs Fierce Biotech · 11h ago
The obvious questions
What is Boulevard Bio's initial funding?
$65 million.
Who is backing Boulevard Bio?
Deerfield Management.
What type of drugs is Boulevard Bio developing?
Targeted autoimmune drugs.
Topics
Related trends
Regeneron backs $75M series A for antibody upstart Infinimmune
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its pipeline of human-derived antibodies.
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.
AbCellera's stock surged after its drug showed promise in treating menopause hot flashes.
Scientists have found a cell that fights infection by detonating. It bursts, kills everything within reach, and five minutes later there is nothing left to show it was ever there
Scientists have discovered a unique immune cell that sacrifices itself to fight infections.
High glucose thickens cancer cells' sugar shield, helping them evade immune attack
Research identifies high glucose levels as a factor in the thickening of cancer cells' sugar shields, potentially masking them from the immune system.
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
LifeMine Therapeutics has secured a massive investment from tech giants Bill Gates and Jeff Bezos, despite conflicting reports on the amount raised.
Gene-edited beagles may offer a future option for people with dog allergies
Kindred Companion Sciences has unveiled the world's first beagles genetically edited via CRISPR to remove the protein responsible for triggering dog allergies.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.